First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

NCT02716012 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Cancer

Interventions

DRUG: MTL-CEBPA
DRUG: Sorafenib 200mg

Sponsor

Mina Alpha Limited